JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $33 | $43 | $34 | $51 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | $11 | $12 | $9 | $10 |
| Gross Profit | $22 | $31 | $25 | $41 |
| % Margin | 65.7% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | $0 | $11 | $9 | $7 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $12 | $12 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $28 | $0 | $0 | $0 |
| Operating Expenses | $28 | $24 | $20 | $21 |
| Operating Income | -$7 | $8 | $5 | $20 |
| % Margin | -20.1% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$1 |
| Pre-Tax Income | -$6 | $7 | $5 | $19 |
| Tax Expense | -$2 | $2 | $2 | $5 |
| Net Income | -$5 | $6 | $4 | $15 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $2 | $2 |
| EBITDA | -$3 | $11 | $7 | $21 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |